Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Covid-19 Vaccination on Management of Chronic Migraine With Botulinum Toxin: A Case Series Publisher



Fetratjoo DH1 ; Jafari E2 ; Togha M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Archives of Clinical Infectious Diseases Published:2023


Abstract

Introduction: Headache worsening has been previously reported following the coronavirus disease 2019 (COVID-19) vaccination. However, COVID vaccination’s influence on managing chronic migraine (CM) with botulinum toxin is yet to be studied. Case Presentation: In this case series, we present five cases of CM, who had responded to abobotulinum toxin type A (BTX-A), but their number of headache days increased after COVID vaccination. Conclusions: In the case of vaccination with COVID vaccines, during the first month of administering botulinum toxin for the management of CM, there might be a decrease in the efficacy of botulinum toxin, which should be explained to the patients. The authors suggest that physicians postpone the administration of BTX-A for chronic migraine management to a later time at their discretion. © 2023, Author(s).